


ITW



CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

February 15, 2005
Date


Signature

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Toth et al.

Serial No.: 10/676,436

Filed: June 30, 2003

For: DELIVERY SYSTEM

Group Art Unit: 1623

Examiner: Krishan, G.

Atty. Dkt. No.: 4050.002900

RESPONSE TO RESTRICTION REQUIREMENT DATED DECEMBER 29, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is submitted in response to the Restriction Requirement dated December 29, 2004 for which the date for response was January 29, 2005.

A request for a one-month extension of time to respond is included herewith along with the required fee. This one-month extension will bring the due date to February 28, 2005, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4050.002900.


In the Restriction Requirement, the Examiner has determined that the pending claims are drawn to four distinct inventions, set forth as:

- Group I: Claims 1-17 and 19, said to be drawn to compounds represented by formula I, and compositions comprising the same, classified in class 536, subclass 18.7;
- Group II: Claims 18-20, said to be drawn to a method of preparation of compounds of formula I, classified 536, subclass 124;
- Group III: Claims 21-22, said to be drawn to a method of delivery of therapeutically useful molecules in the form of a compound of formula I, classified in class 514, subclass 54; and
- Group IV: Claims 23, said to be drawn to a method of treating and preventing a pathological condition, classified in class 514, subclass 8.

In response to the restriction requirement which the Office has imposed, Applicant elects, without traverse, to prosecute claims 1-17 and 19, *i.e.*, the Group I claims.

The Examiner is invited to contact the undersigned at 713.934.4084 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Mark D. Moore, Ph.D.
Reg. No. 42,903
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4084

Date: February 15, 2005